• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Vaccine Data Leak Altering The Investment Case For Moderna Stock?

    Simply Wall St·10/24/2026 20:30:13
    Listen to the news
    • Merck and Moderna reported detailed Phase 3 results for intismeran, an individualized mRNA melanoma therapy given with Keytruda, showing statistically significant improvements in recurrence free and distant metastasis free survival versus Keytruda alone, with no new safety signals. The publication has been accepted by The New England Journal of Medicine.
    • The data highlight both the clinical promise and the operational challenge for Moderna of scaling a personalized cancer vaccine that requires tumor sequencing, custom manufacturing, and close coordination with an existing oncology franchise.
    • The next key question for investors is how these personalized vaccine results shape Moderna’s investment narrative around its broader mRNA platform.

    Scan beyond Moderna and spot other potential breakout healthcare stories with the hand picked 34 healthcare AI stocks that could reshape how medicine is discovered, diagnosed, and delivered.

    What Is Moderna's Investment Narrative?

    To own Moderna, you have to believe the mRNA platform can support a multi product portfolio beyond COVID, across oncology, respiratory disease and pandemic vaccines. The intismeran Phase 3 melanoma win strengthens that story clinically, while the bird flu program and recent launches like mFLUSIVA and mCOMBRIAX show management trying to build recurring vaccine lines. The flip side is clear. The group is still loss making with a US$3.2b net loss and a rich P/S multiple of 35.9x, so execution on pricing, payer uptake and manufacturing efficiency matters a lot.

    In the short term, the melanoma data leak and sharp share price swings highlight how dependent Moderna is on sentiment around a few key readouts and launches. Regulatory filings for intismeran, progress in the broad oncology pipeline and uptake of newer respiratory products look like the main near term catalysts. The business is capital intensive, relies fully on higher risk funding sources and is forecast to remain unprofitable, so any stumble in demand or delays to approvals could quickly change the conversation around that 28.2% forecast top line growth.

    That said, there is a quieter issue sitting underneath all of this that could matter even more if the oncology story plays out...

    There's only one way to know the right time to buy, sell or hold Moderna. Head to Simply Wall St's company report for the latest analysis of Moderna's Fair Value.

    NasdaqGS:MRNA 1-Year Stock Price Chart
    NasdaqGS:MRNA 1-Year Stock Price Chart

    Exploring Other Perspectives

    The sharpest contrast around Moderna today sits in revenue expectations. The most pessimistic analysts were pencilling in just 5.5% annual sales growth and only US$2.6b of revenue by 2029, with earnings of US$451.8m on a 52.7x P/E. That is a far colder view than consensus. The melanoma news could force everyone to revisit those assumptions.

    Explore 4 other Moderna fair value estimates, including one that suggests as much as 51% downside from the current price!

    Reach Your Own Conclusion

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Moderna?

    If Moderna has sharpened your interest in high conviction themes, it can help to widen the lens and compare it with other opportunities that match your risk profile and income needs. The Simply Wall St Screener offers several focused shortlists that can quickly surface companies aligned with your style.